Xencor
Develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
Launch date
Employees
Market cap
CAD2.0b
Enterprise valuation
CAD1.5b (Public information from Sep 2024)
Share price
$20.85 XNCR
Monrovia California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 123m | 275m | 165m | 168m | 68.5m | 116m | 180m |
| % growth | (22 %) | 124 % | (40 %) | 2 % | (59 %) | 69 % | 55 % |
| EBITDA | (76.8m) | 43.8m | (82.5m) | (127m) | (246m) | (199m) | (243m) |
| % EBITDA margin | (63 %) | 16 % | (50 %) | (75 %) | (360 %) | (172 %) | (135 %) |
| Profit | (69.3m) | 82.6m | (55.2m) | (126m) | (244m) | (219m) | (184m) |
| % profit margin | (57 %) | 30 % | (34 %) | (75 %) | (357 %) | (189 %) | (102 %) |
| EV / revenue | 15.5x | 7.3x | 5.7x | 3.3x | 8.9x | 9.3x | 6.0x |
| EV / EBITDA | -24.8x | 46.0x | -11.3x | -4.4x | -2.5x | -5.4x | -4.5x |
| R&D budget | 170m | 193m | 200m | 254m | - | - | - |
| R&D % of revenue | 138 % | 70 % | 121 % | 151 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$12.3m | Series B | ||
$50.0m | Series C | ||
$10.0m | Series D | ||
$15.0m | Series E | ||
| N/A | $6.0m | Debt | |
| N/A | $7.5m | Debt | |
| N/A | $7.6m | Early VC | |
| N/A | N/A | IPO | |
* | N/A | $123m | Post IPO Equity |
* | N/A | N/A | Post IPO Equity |
* | N/A | $226m | Post IPO Equity |
| N/A | $25.0m | Post IPO Equity | |
* | N/A | $175m | Post IPO Equity |
| Total Funding | CAD129m | ||
Related Content
Recent News about Xencor
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.